David Hutton

At the 2023 ASRS meeting in Seattle, Washington, Carl Danzig, MD, caught up with our team to share the exciting results of the GATHER 1 and GATHER 2 clinical trials for avacincaptad pegol for the treatment of geographic atrophy.

Aaron Lee, MD, shared how research and new techniques are expanding the options for deep learning in ophthalmology. He spoke with our team at the 2023 ASRS meeting in Seattle, Washington to share more about this research.

Jennifer I. Lim, MD, FARVO, FASRS shared insights from her presentation on "Detection of early diabetic retinopathy using OCT-A blood flow analysis" with our team.

The American Society of Retina Specialists is hosting its annual meeting this year in Seattle, Washington. Our team caught up with Baruch Kupperman, MD, PHD who is presenting, "Improving vision and dry AMD matching mechanism with the right patient population and stage of disease" to learn more about this topic.

With this funding, the DISCOVER study will evaluate the safety and tolerability of three doses of AXT107 in patients with wet AMD.

APX3330 achieved statistical significance in preventing clinically meaningful progression of diabetic retinopathy.

The results of this study demonstrated the good safety and tolerability of HLX04-O.

The companies plant to create a comprehensive resource that provides valuable insights into health outcomes, medication adherence, and the effectiveness of various treatment protocols.

Genentech will highlight its ophthalmology portfolio at the American Society of Retina Specialists 2023 annual meeting in Seattle, Washington, including a late-breaking presentation on Vabysmo’s effect on epiretinal membrane (ERM) formation in DME compared to aflibercept.

According to 4DMT, the Dose Expansion stage of the PRISM trial is a multicenter, randomized study designed to evaluate the safety and efficacy of 4D-150 at two different dose levels.

Harrow states that this transaction will grant US and Canadian commercial rights to six therapeutics, including two non-prescription brands.

The American Society of Retina Specialists (ASRS) Research and Safety in Therapeutics (ReST) Committee has linked Apellis’ pegcetacoplan injection (Syfovre) with a handful of cases of occlusive retinal vasculitis.

Eye drops developed by Columbia University researchers could prove to be a more effective and comfortable therapy for retinal vein occlusion (RVO).

The machine learning model analyzes retinal images and associated data and recognizes specific features to identify individuals with mild cognitive impairment.

R100 is an adeno-associated virus (AAV) vector invented by 4DMT for intravitreal delivery.

Research has found a new approach that identifies high-risk infants, so that not all preemies need to undergo an invasive eye exam.

Gonzalez shared that the ZETA-1 trial results demonstrate the potential of APX3330 to slow disease progression as well as highlight its favorable safety profile in the diabetic patient population.

The study demonstrated a meaningful increase in the long chain and very long chain polyunsaturated fatty acids whose deficit is associated with dry AMD.

The study's findings demonstrate the accuracy and feasibility of using machine learning models for identifying diabetic retinopathy (DR) progression developed using UWF images.

Get caught up on the approvals and hear directly from Kaushal Solanki, PhD, Founder and CEO of Eyenuk.

The retina is a peripheral part of the central nervous system and shares many similarities with cerebral brain matter.

The study will include 100 patients with the aim of determining effective and ineffective standards of eye injections for AMD to better personalize future medical evaluations.

Caroline Baumal, MD shares an update on visual function data from DERBY and OAKS Studies based on her presentation at the 2023 Clinical Trials at the Summit annual meeting, held in Park City, Utah.

Margaret Chang, MD, MS, spoke with Modern Retina to give an update on avacincaptad pegol for geographic atrophy.

CLS-AX is a proprietary suspension of axitinib for suprachoroidal injection being assessed for the treatment of neovascular age-related macular degeneration (wet AMD).

Prevent Blindness marks its 115th birthday on June 1 by declaring it Prevent Blindness Day.

Reaching target enrollment is an important step toward Nacuity's goal to realize the potential of NPI-001 for patients affected by retinitis pigmentosa.

This positive data supports Coave’s preparations for a registrational trial with CTx-PDE6b in this indication.